Publications by authors named "A Odell"
Article Synopsis
- Tumor Treating Fields (TTFields) use low-intensity electric fields to treat various cancers, including glioblastoma (GBM), but cancer cells can develop resistance to this treatment.
- Research identified a regulatory mechanism involving the prostaglandin E receptor 3 (EP3) and the transcription factor zinc finger 488 (ZNF488) that promotes resistance by aiding the self-renewal of glioma stem-like cells (GSC).
- Targeting either EP3 or ZNF488 re-sensitized resistant GSC to TTFields, suggesting that inhibiting this EP3-ZNF488 axis could prevent or reverse treatment resistance in GBM and other cancers.
Facultative parthenogenesis (FP) has historically been regarded as rare in vertebrates, but in recent years incidences have been reported in a growing list of fish, reptile, and bird species. Despite the increasing interest in the phenomenon, the underlying mechanism and evolutionary implications have remained unclear. A common finding across many incidences of FP is either a high degree of homozygosity at microsatellite loci or low levels of heterozygosity detected in next-generation sequencing data.
View Article and Find Full Text PDFBackground: No previous study has evaluated patients attitudes towards inclusion in an ongoing cardiac arrest clinical trial. The aim of this study was to assess patientś willingness and motives to participate in the ongoing randomized controlled drug trial "Vasopressin and Steroids in addition to Adrenaline in cardiac arrest" (VAST-A trial) in case of an in-hospital cardiac arrest (IHCA).
Objectives: Hospitalized patients, men ≥ 18 and women ≥ 50 years, were asked for informed consent for inclusion in the VAST-A trial in case of an IHCA, the reason for approving or declining inclusion in the trial and baseline characteristics.